Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

RANDALL MARK LEJA

Allopathic & Osteopathic Physicians Pediatrics

NPI
1891058624
CMS profile
759163
Location
GRAND RAPIDS, MI

General Payments · PY2018–2024

$203,821.70

  • Reported across 135 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$37,044.09

30 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $36,768.99 21
Travel and Lodging $275.10 9

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $37,044.09 30

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $23,833.37 11
PY2019 $29,483.36 15
PY2020 $28,008.36 14
PY2021 $28,900.02 14
PY2022 $30,524.83 20
PY2023 $26,027.67 31
PY2024 $37,044.09 30

Payment records · PY2024 (30)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Takeda Pharmaceuticals U.S.A., Inc. $17.03 01/03/2024 Travel and Lodging Undisputed 01/23/2026 1137617575 CMS
Takeda Pharmaceuticals U.S.A., Inc. $591.66 01/03/2024 Consulting Fee Undisputed 01/23/2026 1137617578 CMS
Takeda Pharmaceuticals U.S.A., Inc. $41.92 01/03/2024 Travel and Lodging Undisputed 01/23/2026 1137617582 CMS
Takeda Pharmaceuticals U.S.A., Inc. $700.00 01/03/2024 Consulting Fee Undisputed 01/23/2026 1137617586 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 01/17/2024 Consulting Fee Undisputed 01/23/2026 1137617590 CMS
Takeda Pharmaceuticals U.S.A., Inc. $700.00 02/02/2024 Consulting Fee Undisputed 01/23/2026 1137617593 CMS
Takeda Pharmaceuticals U.S.A., Inc. $40.61 02/02/2024 Travel and Lodging Undisputed 01/23/2026 1137617597 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 02/14/2024 Consulting Fee Undisputed 01/23/2026 1137617601 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.42 02/23/2024 Travel and Lodging Undisputed 01/23/2026 1137617604 CMS
Takeda Pharmaceuticals U.S.A., Inc. $591.66 02/23/2024 Consulting Fee Undisputed 01/23/2026 1137617608 CMS
Takeda Pharmaceuticals U.S.A., Inc. $40.20 02/23/2024 Travel and Lodging Undisputed 01/23/2026 1137617612 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,291.66 02/23/2024 Consulting Fee Undisputed 01/23/2026 1137617615 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 03/11/2024 Consulting Fee Undisputed 01/23/2026 1137617619 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,556.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 1137617623 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,556.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 1137617627 CMS
Takeda Pharmaceuticals U.S.A., Inc. $41.54 06/05/2024 Travel and Lodging Undisputed 01/23/2026 1137617630 CMS
Takeda Pharmaceuticals U.S.A., Inc. $756.00 06/05/2024 Consulting Fee Undisputed 01/23/2026 1137617634 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.42 06/10/2024 Travel and Lodging Undisputed 01/23/2026 1137617638 CMS
Takeda Pharmaceuticals U.S.A., Inc. $639.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 1137617641 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,556.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 1137617645 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,556.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137617649 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,556.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 1137617653 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,556.00 09/11/2024 Consulting Fee Undisputed 01/23/2026 1137617657 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.42 10/02/2024 Travel and Lodging Undisputed 01/23/2026 1137617660 CMS
Takeda Pharmaceuticals U.S.A., Inc. $639.00 10/02/2024 Consulting Fee Undisputed 01/23/2026 1137617664 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,556.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 1137617668 CMS
Takeda Pharmaceuticals U.S.A., Inc. $41.54 10/11/2024 Travel and Lodging Undisputed 01/23/2026 1137617672 CMS
Takeda Pharmaceuticals U.S.A., Inc. $756.00 10/11/2024 Consulting Fee Undisputed 01/23/2026 1137617675 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,556.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 1137617679 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,556.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 1137617683 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.